Moloxin (Moxifloxacin)

Moxifloxacin, the active ingredient in Moloxin, is a fluoroquinolone antibiotic presented as an injection for intravenous use. It treats a range of serious bacterial infections in adult patients.

GNH USA supplies Moloxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moloxin is a fluoroquinolone antibiotic indicated for several serious bacterial infections.

Community‑acquired bacterial pneumonia: rapid bacterial eradication leading to clinical cure. Acute bacterial sinusitis: resolution of sinus infection symptoms. Acute exacerbations of chronic bronchitis: reduction of bacterial load and improvement of airflow. Skin and skin structure infections: effective treatment of Gram‑positive and Gram‑negative pathogens. Intra‑abdominal infections: broad‑spectrum coverage for mixed aerobic and anaerobic organisms.

Moloxin may cause a variety of adverse reactions. Monitoring and prompt reporting are recommended.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Rash - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation and potential arrhythmias - Severe allergic reactions including anaphylaxis - Clostridioides difficile‑associated colitis - Hepatic failure - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When using Moloxin, clinicians should consider several safety measures.

Renal impairment: adjust monitoring as drug clearance may be reduced. Hepatic impairment: use with caution due to hepatic metabolism. History of tendon disorders: avoid because of increased risk of tendon rupture. QT prolongation risk: contraindicated in patients with known prolonged QT or on other QT‑prolonging agents. Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moloxin can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: additive toxicity. - Concurrent use of QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmia. - Systemic corticosteroids: increased risk of tendon rupture. - Antacids containing aluminum or magnesium (for oral forms): may reduce absorption (relevant for oral equivalents). - Strong CYP1A2 inhibitors: may raise moxifloxacin plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Theophylline: possible increase in plasma concentration; watch for toxicity. - Caffeine and other CYP1A2 substrates: may experience elevated levels; adjust intake as needed.